Literature DB >> 12474230

Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours.

Raymond Lai1, George Z Rassidakis, L Jeffrey Medeiros, Vasiliki Leventaki, Micheal Keating, Timothy J McDonnell.   

Abstract

The pathogenesis of mantle cell lymphoma (MCL) is incompletely understood, although cyclin D1 overexpression leading to deregulated cell proliferation is probably important. Recent data suggest that interleukin (IL)-10 can increase the proliferative activity of MCL cells. STAT3 (signal transducer and activator of transcription 3) is the signal transducer of IL-10, and STAT3 is activated by phosphorylation. The hypothesis of this study is that STAT3 is activated in MCL. The expression of the two phosphorylated (i.e. active) forms of STAT3, pSTAT3-tyr (phosphorylated at the tyrosine(705) residue) and pSTAT3-ser (phosphorylated at the serine(727) residue), was assessed in four MCL cell lines and 12 MCL tumours using western blots and/or immunofluorescence staining techniques. All MCL cell lines expressed STAT3, but only one had detectable pSTAT3-tyr and none had pSTAT3-ser. Addition of IL-10 rapidly resulted in expression of pSTAT3-tyr but not pSTAT3-ser. All eight cases of frozen MCL tumours examined had detectable pSTAT3-tyr and pSTAT3-ser. Immunofluorescence studies using four formalin-fixed, paraffin wax-embedded MCL tumours demonstrated cytoplasmic localization of STAT3, as opposed to the nuclear localization of the pSTAT3 species. In conclusion, these findings provide evidence that STAT3 is constitutively activated in MCL, supporting the concept that STAT3 signalling may be important in the pathogenesis of these tumours. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12474230     DOI: 10.1002/path.1253

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

2.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

4.  Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model.

Authors:  Yang Cao; Xiaoxi Zhou; Mi Zhou; Danmei Xu; Quanfu Ma; Peilin Zhang; Xiaoyuan Huang; Qinlu Li; Ding Ma; Jianfeng Zhou
Journal:  Cancer Biol Ther       Date:  2014-06-10       Impact factor: 4.742

Review 5.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

6.  Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

Authors:  Lan V Pham; Archito T Tamayo; Changping Li; William Bornmann; Waldemar Priebe; Richard J Ford
Journal:  Mol Cancer Ther       Date:  2010-07-06       Impact factor: 6.261

7.  Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis.

Authors:  Michail S Lionakis; Johanna Lahdenranta; Jessica Sun; Wei Liu; Russell E Lewis; Nathaniel D Albert; Renata Pasqualini; Wadih Arap; Dimitrios P Kontoyiannis
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

8.  Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Authors:  Fanny Baran-Marszak; Mohand Boukhiar; Stéphanie Harel; Christelle Laguillier; Claudine Roger; Remy Gressin; Antoine Martin; Remi Fagard; Nadine Varin-Blank; Florence Ajchenbaum-Cymbalista; Dominique Ledoux
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

Review 9.  New insights into the regulation of human B-cell differentiation.

Authors:  Heike Schmidlin; Sean A Diehl; Bianca Blom
Journal:  Trends Immunol       Date:  2009-05-15       Impact factor: 16.687

10.  MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.

Authors:  Baoyu Wu; Jingyu Li; Han Wang; Qian Wu; Hui Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.